Blue Cross Blue Shield MA trigger point injections Coverage

Coverage Criteria

Medically necessary criteria — Myofascial pain syndrome

Trigger point injections with anesthetic and/or corticosteroid are considered MEDICALLY NECESSARY for myofascial pain syndrome when ALL of the following are met:

Medically necessary criteria — Myofascial pain syndrome: There is a regional pain complaint in the expected distribution of referral pain from a trigger point; AND there is spot tenderness in a palpable taut band in a muscle; AND there is restricted range of motion; AND conservative therapy (eg, physical therapy, active exercises, ultrasound, heating or cooling, massage, activity modification, or pharmacotherapy) for 6 weeks fails or is not feasible; AND trigger point injections are provided as a component of a comprehensive therapy program; AND no more than 4 injections are given in a rolling 12-month period.see individual nodes

All listed conditions must be met.

Frequency limitation

Key coverage constraint documented in policy history

Frequency limit: No more than 4 trigger point injections are given in a rolling 12-month period.4 per 12 months

Stated in 1/2025 clarification and present in original 6/2020 policy.

Trigger point and tender point injections are considered INVESTIGATIONAL for indications other than myofascial pain syndrome that meets the medically necessary criteria. The policy explicitly lists complex regional pain syndrome, abdominal wall pain, fibromyalgia, and procedures using ultrasound guidance as investigational for these indications; thus injections for these other conditions do not meet the policy’s coverage criteria.

The policy excerpt does not present a separate explicit exclusion list beyond the investigational statements. Policy history and statements were noted as unchanged across reviews, and no additional exclusions are enumerated in the provided excerpt.

The available evidence is described as insufficient to determine an improvement in net health outcome for trigger or tender point injections in several indications. Specifically, evidence is insufficient for complex regional pain syndrome, abdominal wall pain, and fibromyalgia, based on limited or single randomized trials and case series, and therefore these indications are considered investigational per the policy.

Within the excerpted policy text and documented policy history, there are no additional explicit statements labeling any services as not medically necessary beyond the investigational determinations noted. Policy statements were reported as unchanged in successive reviews.

Coding

Prior Authorization

Prior Authorization Required

Provider Action: Inpatient prior authorization required.

Inpatient prior authorization required

Covered CPT CodesCPTCovered

20552	Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s)
20553	Injection(s); single or multiple trigger point(s), 3 or more muscles

Covered ICD-10 Diagnosis Codes (when criteria met)ICD-10Covered

M79.10	Myalgia, unspecified site
M79.11	Myalgia of mastication muscle
M79.12	Myalgia of auxiliary muscles, head and neck
M79.18	Myalgia, other site

Documentation Required

Coding and documentation — providers should report services using up-to-date procedure and diagnosis codes

Required documentation: medical records must document the clinical indication, relevant history and exam findings, prior conservative treatments and response, number and location of trigger points treated, the CPT/ICD-10 codes billed, and any applicable modifiers. Retain documentation to support medical necessity and submit when requested for prior authorization or claims review. Failure to provide adequate documentation may result in claim denial or recoupment.

Provider Actions and Administrative Requirements

Prior Authorization

Outpatient prior authorization not required for Commercial products

Prior authorization is not required for outpatient trigger point injections for Commercial Managed Care (HMO and POS), PPO, and Indemnity members.

Outpatient prior authorization is not required for Commercial Managed Care (HMO and POS), Commercial PPO, and Indemnity.

Prior Authorization

No explicit prior authorization instructions in excerpt

The policy excerpt contains no additional, specific prior authorization instructions for outpatient services beyond the product-level guidance.

Policy history and excerpt do not provide explicit stepwise prior authorization procedures or forms.

Note

Verify full medical necessity criteria before performing trigger point injections

Ensure patient meets all medically necessary criteria before performing injections: regional pain pattern, palpable trigger point with taut band and spot tenderness, restricted range of motion, ≥6 weeks of failed or infeasible conservative therapy, injection provided as part of comprehensive therapy, and adherence to the frequency limit of ≤4 injections per rolling 12 months.

Conservative Treatment Requirements

Conservative therapy for 6 weeks fails or is not feasible prior to considering trigger point injections.

Conservative therapy must fail for at least 6 weeks (or be not feasible) prior to considering trigger point injections.

Conservative therapy requirement: Conservative therapy (eg, physical therapy, active exercises, ultrasound, heating or cooling, massage, activity modification, or pharmacotherapy) for 6 weeks fails or is not feasible.6 weeks

Examples of conservative therapy are provided in policy.

Frequency Limits

Trigger point injections — policy limit

LimitNo more than 4 trigger point injections are given in a rolling 12‑month period.

Applies toTrigger point injections for myofascial pain syndrome when provided as part of a comprehensive therapy program.

Enforcement noteExceeding this limit may trigger denial or noncoverage per policy history and authorization guidance.

Trigger point injections — frequency cap (duplicate)

Limit (duplicate entry)No more than 4 trigger point injections in a rolling 12‑month period.

Documented inStated in the original 6/2020 policy and clarified in 1/2025 policy update.

Definitions

Trigger point — definition

TermTrigger point

DefinitionDiscrete, focal, hyperirritable spots within a taut band of skeletal muscle fibers that produce local and/or referred pain when stimulated.

Clinical featuresAssociated with local ischemia, hypoxia, lowered pH, local and referred pain, and altered muscle activation patterns.

Tender point — definition

TermTender point

DefinitionFocal areas of hyperalgesia that tend to occur at muscle‑tendon junctions and lack a taut band of muscle tissue or local hyperirritability when palpated.

Clinical note

Background

Trigger points are described as discrete, focal, hyperirritable spots within a taut band of skeletal muscle that produce local and/or referred pain when stimulated; tender points produce local pain but lack a taut band. These physiologic distinctions underlie the clinical rationale for targeted injections into trigger points as part of a broader management plan for myofascial pain syndrome.

Not Covered / Investigational

The policy identifies several procedures and indications that are not supported by current evidence and are therefore classified as investigational or not covered. Examples explicitly called out include ultrasound-guided trigger point injections (considered investigational) and trigger/tender point injections for complex regional pain syndrome, abdominal wall pain, and fibromyalgia, for which the evidence is limited (case series or single RCTs) and deemed insufficient to demonstrate a net health benefit. The policy history reiterates these positions and documents that policy statements were unchanged during reviews.

This inventory entry duplicates the not-covered/investigational items: ultrasound-guided trigger point injections and injections for complex regional pain syndrome, abdominal wall pain, and fibromyalgia are described in the policy as investigational due to insufficient evidence. Policy history notes no change to these determinations during reviews.

Duplicate entry reiterating that trigger/tender point injections for indications other than qualifying myofascial pain syndrome — including complex regional pain syndrome, abdominal wall pain, and fibromyalgia — are considered investigational based on the limited or mixed evidence summarized in randomized trials and case series.

Another duplicate restating the investigational status of ultrasound-guided trigger point injections and injections for complex regional pain syndrome, abdominal wall pain, and fibromyalgia; the evidence cited in the policy summaries is judged insufficient to support coverage for these indications.

The provided excerpt does not include a standalone list of procedures or indications specifically labeled not covered beyond the investigational determinations already described. The policy history confirms that statements were unchanged across annual reviews and that the operational frequency limit (no more than 4 injections in a rolling 12-month period) was clarified in 1/2025.

OpenPayer

Trigger Point and Tender Point Injections

Coverage Criteria

Coding

Provider Actions and Administrative Requirements

Conservative Treatment Requirements

Frequency Limits

Definitions

Background

Not Covered / Investigational